⌕
Burning Rock Biotech · BNR · Nasdaq
Tenet 42 · Weak
Compare
$13.32+1.91%At closeTenet 42 · Weak
$13.32+0.25 (+1.91%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

Burning Rock Biotech (BNR) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

5 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue compounds ~−0.8%/yr (FY21→FY25), net margin −10.3%.
The lines that matter · FY21–FY25
Revenue ($M)▲9.2%
77.2
FY21→FY25CAGR −0.8%/yr
Net income ($M)▲83.3%
−7.9
FY21→FY25CAGR —
Free cash flow ($M)▲64.0%
−4.8
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+2.0%

104.2mn → 106.3mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.

Capex
$750.6K

steady at 1.0% of revenue (+1.1% YoY).

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)77.2Revenue−19.5COGS57.6Gross profit−23.8R&D−18.0SG&A−7.8Op income−0.1Tax & other−7.9Net income

-10¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
806040200%sector median net margin ~3%FY21FY25

Over this window: gross 71.7% → 74.7%. Net margin -10.3% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemFY25 †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
77,157.277,157.270,667.375,696.181,661.879,694.6▲9.2%−0.8%
Cost of revenue
19,541.319,541.321,018.724,536.726,561.422,552.2▼7.0%−3.5%
Gross profit
57,615.957,615.949,648.651,159.555,100.557,142.5▲16.0%+0.2%
Research & development
23,808.323,808.331,823.648,876.261,165.157,724.9▼25.2%−19.9%
Selling, general & admin
18,030.618,030.635,844.361,665.882,393.476,931.9▼49.7%−30.4%
Total operating expenses
65,458.765,458.798,634.0145,431.3197,246.1182,219.2▼33.6%−22.6%
Operating incomefeeds ROC rank
−7,842.7−7,842.7−48,985.4−94,271.9−142,145.7−125,076.7▲84.0%—
Other income, net
150.9150.92,304.12,538.11,617.9198.7——
Pretax income
−7,691.9−7,691.9−46,681.3−91,733.8−140,527.8−124,878.1▲83.5%—
Income tax
222.5222.5806.2336.3287.8141.1▼72.4%+12.1%
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−7,914.4−7,914.4−47,487.6−92,070.2−140,815.5−125,019.1▲83.3%—
Per share
Diluted EPSbuyback-sensitive
——A—A—A—A—A——
Diluted shares (mn)
106.30106.30102.94102.40103.91104.21▲3.3%+0.5%
Margins
Gross margin68th pct in Healthcare
74.7%74.7%70.3%67.6%67.5%71.7%▲4.4pp+3.0pp
Operating margin
−10.2%−10.2%−69.3%−124.5%−174.1%−156.9%▲59.2pp+146.8pp
Net margin27th pct in Healthcare
−10.3%−10.3%−67.2%−121.6%−172.4%−156.9%▲56.9pp+146.6pp
† FY25 = fiscal 2025, through 2025-12-31; the trailing year is not available.A Withheld by our checks.
FY18 – FY20 · 3 more years
Unlock the full history →
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-04-28 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Burning Rock Biotech's revenue last fiscal year?

Burning Rock Biotech reported revenue of $77.2M in fiscal 2025, up 9.2% from fiscal 2024.

What was Burning Rock Biotech's net income?

Burning Rock Biotech reported net income of −$7.9M in fiscal 2025, a net margin of −10.3%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.